Physician profile
Luis E Colon
NPI 1255391686
$3,917.01
in general payments reported to CMS, 2019-2025
32 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $234 · 2021: $657 · 2022: $406 · 2023: $758 · 2024: $548 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $511.60 | 2021-2022 | |
| Abbvie INC. | $492.19 | 2022-2025 | Lumigan, Vuity, Durysta |
| Glaukos Corporation | $418.28 | 2019-2025 | Idosetr, Istent Infinite |
| Bausch & Lomb Americas INC. | $349.82 | 2022-2025 | Vyzulta, Zylet, Alrex |
| Allergan, INC. | $295.50 | 2019-2022 | |
| Oyster Point Pharma, INC. | $253.85 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $244.27 | 2019 | |
| Ocular Therapeutix, INC. | $216.92 | 2020-2023 | Dextenza |
| Alcon Vision LLC | $140.30 | 2019-2025 | Tryptyr, Rocklatan |
| Amgen INC. | $121.18 | 2024 | Tepezza |
| Harrow Eye, LLC | $101.62 | 2024-2025 | Vevye |
| Apellis Pharmaceuticals, INC. | $95.81 | 2023 | Syfovre |
| Novartis Pharmaceuticals Corporation | $90.33 | 2019-2023 | |
| Thea Pharma INC. | $66.83 | 2023-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $65.78 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $48.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $45.75 | 2022-2024 | Xarelto |
| Biotissue Holdings INC. | $41.33 | 2019-2021 | |
| Merz North America, INC. | $36.31 | 2025 | |
| Eyevance Pharmaceuticals LLC | $35.73 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $35.59 | 2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $27.01 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $23.51 | 2021 | |
| Tearlab Corp | $22.90 | 2019 | |
| Rayner Intraocular Lenses Limited | $21.32 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Johnson & Johnson Surgical Vision, INC. | $20.04 | 2021 | |
| Dompe US, INC. | $19.83 | 2024 | Oxervate |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $18.17 | 2024 | |
| Omeros Corporation | $15.73 | 2021 | |
| Lkc Technologies, INC. | $14.70 | 2024 | |
| Eyepoint US, INC. | $13.85 | 2019 | |
| Shire North American Group INC | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Colon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.